The U.S. Food and Drug Administration announced a second tranche of Commissioner’s National Priority Vouchers (CNPVs), accelerating review pathways for six drugs that align with administration priorities; the list included high‑profile obesity candidates from Eli Lilly and Novo Nordisk. The program is part of a broader effort to shorten review timelines and encourage domestic manufacturing. The agency’s selections underscore political and commercial pressure to expedite high‑impact therapies — notably GLP‑1 and related weight‑loss candidates — and could shift approval calendars for oral and injectable obesity medicines. Sponsors receiving vouchers gain the right to compressed review windows that may materially change launch timing and competitive dynamics. Stakeholders will monitor how swift review timelines interact with payer negotiations and manufacturing obligations tied to the CNPV program, and whether future voucher allocations become a strategic lever for large pharma.